Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 1/20 | 0.38 |
| ▸ | FEN1 | P39748 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.34 |
| ▸ | MMP2 | P08253 | 3/20 | 0.32 |
| ▸ | MMP8 | P22894 | 3/20 | 0.32 |
| ▸ | MMP1 | P03956 | 2/20 | 0.32 |
| ▸ | MMP9 | P14780 | 2/20 | 0.32 |
| ▸ | KAT6A | Q92794 | 5/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | PYGL | P06737 | 1/20 | 0.31 |
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16670640 | 1.00 | ALOX5AP (0.38) | ALOX5APFEN1MAPTPDE10AMMP2 | |
| SCHEMBL16682001 | 0.94 | MMP2 (0.39) | ALOX5APFEN1MAPTPDE10AMMP2 | |
| SCHEMBL18041063 | 0.94 | MMP2 (0.39) | ALOX5APFEN1MAPTPDE10AMMP2 | |
| SCHEMBL16670376 | 0.93 | ALOX5AP (0.34) | ALOX5APFEN1PDE10AMMP2MMP8 | |
| SCHEMBL16670373 | 0.93 | ALOX5AP (0.34) | ALOX5APFEN1PDE10AMMP2MMP8 | |
| SCHEMBL16669969 | 0.93 | KCNH2 (0.33) | ALOX5APFEN1MAPTPDE10AMMP2 | |
| SCHEMBL16669968 | 0.93 | KCNH2 (0.33) | ALOX5APFEN1MAPTPDE10AMMP2 | |
| SCHEMBL16670794 | 0.92 | SMN1; SMN2 (0.33) | ALOX5APFEN1MAPTPDE10AMMP2 | |
| SCHEMBL16670792 | 0.92 | SMN1; SMN2 (0.33) | ALOX5APFEN1MAPTPDE10AMMP2 | |
| SCHEMBL18181419 | 0.90 | ALOX5AP (0.31) | ALOX5APFEN1MAPTPDE10ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10035760-B2 | Inhibitors of human immunodeficiency virus replication | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2018-07-31 | — | — | US | disclosed |
| US-10035760-B2 | Inhibitors of human immunodeficiency virus replication | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2018-07-31 | — | — | US | disclosed |
| US-20160257645-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2016-09-08 | — | — | US | disclosed |
| EP-3060554-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | Bristol-Myers Squibb Company (US) | 2016-08-31 | — | — | EP | disclosed |
| WO-2015061518-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160257645-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, POLR1E, POLR1G | ALOX5AP 3760/4885FEN1 274/4885MAPT 1886/4885 |
| US-10035760-B2 | Inhibitors of human immunodeficiency virus replication | EIF2AK2, POLR1G, POLR1E | ALOX5AP 3365/4885FEN1 226/4885MAPT 2033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.